Avidity Biosciences, Inc. — Director's Dealing 2024

May 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2024-05-07

Reporting Person: Boyce Sarah (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-07	Common Stock	M	28000	$1.24	Acquired	140117	Direct
2024-05-07	Common Stock	S	28000	$25.5375	Disposed	112117	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-07	Stock Option (Right to Buy)	$1.24	M	28000	Disposed	2029-12-17	Common Stock (28000)	Direct

Footnotes

F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

F2: Includes the following securities previously acquired by the Reporting Person: (i) 107,408 restricted stock units under the Issuer's 2020 Incentive Award Plan and (ii) 4,709 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan.

F3: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.01 to $26.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.